Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Primary Membranous Nephropathy
NCT07289763Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Primary completion
- Aug 2027
- Modality
- Biological product
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2173 in primary membranous nephropathy (PMN), sponsored by Hengrui Therapeutics. Started Dec 2025; status: recruiting.
02
Drugs
SHR-2173
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07289763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289763.